ProMIS Neurosciences
Max Milbury began their professional career as an Audit Associate at KPMG in 2012. Max then progressed to become a Senior Audit Associate at KPMG US in 2014. Following this, they took on the role of Audit Manager at KPMG in 2017. Subsequently, they moved to Q-State Biosciences, where they held positions as a Senior Accounting Manager and Controller. In 2022, Max Milbury became the Director of Finance at ProMIS™ Neurosciences, Inc.
Max Milbury earned a Bachelor's degree in Accounting from the University of Maryland - College Park.
This person is not in any offices
ProMIS Neurosciences
ProMIS™ Neurosciences, Inc. is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).